Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...

Taking tiny doses of GLP-1 medication has been touted for weight management, perimenopause symptoms, even longevity. But is ...

Many patients with overweight or obesity discontinue glucagon-like peptide-1 receptor agonist therapy within one year.

Many patients with overweight or obesity discontinue GLP-1 receptor agonist therapy within 1 year, with higher discontinuation rates seen for those without type 2 diabetes.

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...

GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small study. Here's what doctors have to say.

The drug semaglutide has been linked to a lower risk of alcoholism before, but now we have strong evidence that it really ...

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 study suggesting a potential role for GLP-1 agonists in PD.

As glucagon-like peptide 1 (GLP-1 ... Only the marked doses on the single-use, fixed-dose pens, at 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg are approved and represent an authentic FDA-approved ...

Patients with diabetes mellitus exhibit hyperglucagonemia, or excess glucagon secretion, which may be the underlying cause of the hyperglycemia of diabetes. Defective alpha cell secretory responses to ...

Then there’s the MG Cyberster’s size. At 4.54 metres long and 1.91 metres wide, it’s bigger than a 911 Turbo, while a gross weight of 2.2 tonnes is around 200kg more than the Porsche’s ...